Vaping Likely Causes Lung and Oral Cancer, Major Review Concludes

A comprehensive review published June 21 in the journal Carcinogenesis has reached the most direct conclusion yet on e-cigarettes and cancer: nicotine-based vapes are likely to cause cancers of the lung and oral cavity.

The analysis was led by Adjunct Professor Bernard Stewart AM, a cancer researcher at UNSW Sydney, and drew on investigators from the University of Queensland, Flinders University, the University of Sydney, and three Australian teaching hospitals. The team included pharmacists, epidemiologists, thoracic surgeons, and public health researchers, a deliberately cross-disciplinary lineup designed to evaluate the evidence from every angle at once, according to the UNSW newsroom.

The review didn't rely on a single line of evidence. Researchers sorted the literature into three buckets: human studies showing biomarkers of DNA damage, oxidative stress, and inflammation; animal studies in which mice exposed to vape aerosol developed lung tumors; and lab analyses showing how compounds in vape liquid, including known carcinogens, damage cells at the molecular level. They also weighed case reports of heavy vapers presenting with aggressive oral cancers at relatively young ages, where traditional risk factors like smoking or HPV infection were absent or limited, as reported by ScienceAlert.

The honest caveat is timing. E-cigarettes weren't widely used until the early 2000s, which means population-level mortality data comparable to decades of cigarette research simply don't exist yet. Stewart's team acknowledged that gap but argued the convergent early signals are strong enough to act on now rather than wait for the body count. As reviewed in the journal Carcinogenesis, the authors concluded that nicotine-based vapes are "likely to be carcinogenic to humans" even in the absence of those long-term outcome studies.

For clinicians, that framing matters. Oncologists and pulmonologists have been navigating patient conversations about vaping for years without a clear evidence-based answer on cancer risk. This review moves the conversation from "we're not sure" to "the early signs are consistent and concerning."

The timing puts the findings in direct tension with U.S. regulatory policy. In May 2026, the FDA authorized four flavored e-cigarettes for sale and issued guidance that will let certain flavored e-cigarettes and nicotine pouches remain on store shelves while the agency works through its review backlog, according to the American Lung Association. That includes fruit flavors like mango and blueberry. The Lung Association's president publicly condemned the decision, noting it reverses years of agency policy built around protecting kids from flavored products.

The youth exposure picture is genuinely mixed. According to the 2024 National Youth Tobacco Survey, current e-cigarette use among middle and high schoolers has fallen from 5.38 million students in 2019 to 1.63 million in 2024, a steep drop that public health groups credit partly to earlier flavor restrictions and FDA education campaigns. That's real progress. But among the kids still vaping, close to 90 percent use flavored products, with fruit flavors the most popular, per the same survey data published by the FDA.

What the Carcinogenesis review adds is a clearer biological explanation for why that lingering 1.6 million matters. People who started vaping as teenagers in the mid-2010s are now in their mid-to-late twenties. They're the first cohort to have used these products for a decade or longer, and they're only now entering the window where early-stage cancer biomarkers become clinically relevant.

The review doesn't settle every question. The exact magnitude of risk, how it compares to combustible cigarettes, and whether it varies by device type or liquid chemistry all remain open. But the authors say the evidence is consistent enough that waiting for definitive long-term data repeats the same mistake made with cigarettes in the 1950s, watching the signal build for decades before acting.

For patients who vape and are asking their clinicians what this means for them, the honest answer right now is: the risk looks real, we can't quantify it precisely yet, and no safe threshold has been established.

Sources cited:
- Carcinogenesis (via UNSW Sydney Newsroom) (https://www.unsw.edu.au/newsroom/news/2026/03/vaping-likely-to-cause-cancer-new-findings)
- ScienceAlert (https://www.sciencealert.com/vaping-likely-causes-cancer-major-study-finds)
- Medical Daily (https://www.medicaldaily.com/vaping-causes-lung-oral-cancer-unsw-sydney-carcinogenesis-review-2026-475743)
- American Lung Association (https://www.lung.org/blog/flavored-tobacco-fda-decision)
- FDA National Youth Tobacco Survey results (https://www.fda.gov/tobacco-products/youth-and-tobacco/results-annual-national-youth-tobacco-survey-nyts)